Obinutuzumab for previously untreated chronic lymphocytic leukemia

被引：2
|
作者：
不详
机构：
来源：
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY | 2014年 / 12卷 / 04期
关键词：
D O I：
10.12788/jcso.0032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：118 / 120
页数：3
相关论文
共 50 条
  • [41] Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia
    Brown, Jennifer R.
    ONCOLOGY-NEW YORK, 2015, 29 (06): : 442 - +
  • [42] Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia
    Wierda, William G.
    Kipps, Thomas J.
    Duerig, Jan
    Griskevicius, Laimonas
    Stilgenbauer, Stephan
    Mayer, Jiri
    Smolej, Lukas
    Hess, Georg
    Griniute, Rasa
    Hernandez-Ilizaliturri, Francisco J.
    Padmanabhan, Swaminathan
    Gorczyca, Michele
    Chang, Chai-Ni
    Chan, Geoffrey
    Gupta, Ira
    Nielsen, Tina G.
    Russell, Charlotte A.
    BLOOD, 2011, 117 (24) : 6450 - 6458
  • [43] A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia
    Cheng, Mindy M.
    Goulart, Bernardo
    Veenstra, David L.
    Blough, David K.
    Devine, Emily Beth
    CANCER TREATMENT REVIEWS, 2012, 38 (08) : 1004 - 1011
  • [44] Total cost of care with 12 months fixed duration of venetoclax plus obinutuzumab in previously-untreated chronic lymphocytic leukemia (CLL) patients
    Cho, Sang Kyu
    Manzoor, Beenish
    Sail, Kavita
    Ravelo, Arliene
    Shapouri, Sheila
    Sharmokh, Simon
    Kapustyan, Tatyana
    Johnson, Scott
    Parise, Helene
    Virabhak, Suchin
    Davids, Matthew
    LEUKEMIA & LYMPHOMA, 2020, 61 : 57 - 57
  • [45] A cross-trial comparison of single-agent ibrutinib versus chlorambucil-obinutuzumab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Tedeschi, Alessandra
    Greil, Richard
    Demirkan, Fatih
    Robak, Tadeusz
    Moreno, Carol
    Barr, Paul M.
    Anz, Bertrand
    Simpson, David
    Gaidano, Gianluca
    Bairey, Osnat
    Stevens, Don
    Gill, Devinder
    Flinn, Ian W.
    Kipps, Thomas J.
    Burger, Jan A.
    Lin, Jennifer
    Webb, Thomas
    Fedorov, Viktor
    Styles, Lori
    Gribben, John G.
    HAEMATOLOGICA, 2020, 105 (04)
  • [46] Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
    Lei, Matthew M.
    Sorial, Mark N.
    Lou, Uvette
    Yu, Michelle
    Medrano, Andrea
    Ford, Josie
    Nemec, Ronald A.
    Abramson, Jeremy S.
    Soumerai, Jacob D.
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 653 - 659
  • [47] Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China
    Li, Mengya
    Zhong, Xiaoyan
    Zhang, Chengbin
    Luo, Hongli
    Luo, Li
    Huang, Yilan
    Jiang, Longyang
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [48] Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States
    Sang Kyu Cho
    Beenish S. Manzoor
    Kavita R. Sail
    Hélène Parisé
    Arliene Ravelo
    Sheila Shapouri
    Tatyana Kapustyan
    Simon Sharmokh
    Suchin Virabhak
    Matthew S. Davids
    Scott Johnson
    PharmacoEconomics, 2020, 38 : 941 - 951
  • [49] Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
    Al-Sawaf, Othman
    Robrecht, Sandra
    Zhang, Can
    Olivieri, Stefano
    Chang, Yi Meng
    Fink, Anna Maria
    Tausch, Eugen
    Schneider, Christof
    Ritgen, Matthias
    Kreuzer, Karl-Anton
    Sivchev, Liliya
    Niemann, Carsten Utoft
    Schwarer, Anthony
    Loscertales, Javier
    Weinkove, Robert
    Strumberg, Dirk
    Kilfoyle, Allanah
    Manzoor, Beenish S.
    Jawaid, Dureshahwar
    Emechebe, Nnadozie
    Devine, Jacob
    Boyer, Michelle
    Runkel, Eva D.
    Eichhorst, Barbara
    Stilgenbauer, Stephan
    Jiang, Yanwen
    Hallek, Michael
    Fischer, Kirsten
    BLOOD, 2024, 144 (18) : 1924 - 1935
  • [50] MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (vol 18, pg 3689, 2022)
    Ryan, Christine E.
    Davids, Matthew S.
    Hermann, Richard
    Shahkarami, Mina
    Biondo, Juliana
    Abhyankar, Sarang
    Alhasani, Hasan
    Sharman, Jeff P.
    Mato, Anthony R.
    Roeker, Lindsey E.
    FUTURE ONCOLOGY, 2023,
12345